Brief: Travere Therapeutics Q1 EPS USD -0.4
04/05/2026 21:01
May 04 (Reuters) - Travere Therapeutics Q1 product sales USD 124.492 million. Q1 net income USD -37.102 million Q1 operating income USD -36.915 million Q1 operating expenses USD 164.114 million
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule